Evidence map›Paper›PMID 38737790›Full record

ArticleJournal of biomedical optics2024

Functional hemodynamic imaging markers for the prediction of pathological outcomes in breast cancer patients treated with neoadjuvant chemotherapy.

Bin Deng, Ailis Muldoon, Jayne Cormier, Nathaniel D Mercaldo, Elizabeth Niehoff, Natalie Moffett, Mansi A Saksena, Steven J Isakoff, Stefan A Carp

Abstract read
In one paragraph

Article in Journal of biomedical optics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Bin DengMassachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Charlestown, Massachusetts, United States.ORCID 0000-0001-8347-1104
Ailis MuldoonMassachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Charlestown, Massachusetts, United States.
Jayne CormierMassachusetts General Hospital, Breast Imaging Division, Department of Radiology, Boston, Massachusetts, United States.
Nathaniel D MercaldoHarvard Medical School, Boston, Massachusetts, United States.ORCID 0000-0003-1658-6598
Elizabeth NiehoffMassachusetts General Hospital, Cancer Center, Boston, Massachusetts, United States.
Natalie MoffettMassachusetts General Hospital, Cancer Center, Boston, Massachusetts, United States.
Mansi A SaksenaHarvard Medical School, Boston, Massachusetts, United States.
Steven J IsakoffHarvard Medical School, Boston, Massachusetts, United States.
Stefan A CarpMassachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Charlestown, Massachusetts, United States.ORCID 0000-0003-4617-3233

Funding

Dynamic Optical Imaging Biomarkers of Tumor Response to TherapyR01CA187595 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CARP, STEFAN ALEXANDRU · 2015 to 2019
$2.6M
Multiparametric multimodal imaging for breast cancer neoadjuvant chemotherapy monitoringK01EB027726 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI DENG, BIN · 2019 to 2022
$563k
NCI NIH HHS R01 CA187595NIBIB NIH HHS K01 EB027726
6 · The paper itself

Abstract

Significance: Achieving pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT) is a significant predictor of increased likelihood of survival in breast cancer patients. Early prediction of pCR is of high clinical value as it could allow personalized adjustment of treatment regimens in non-responding patients for improved outcomes. Aim: We aim to assess the association between hemoglobin-based functional imaging biomarkers derived from diffuse optical tomography (DOT) and the pathological outcome represented by pCR at different timepoints along the course of NACT. Approach: Twenty-two breast cancer patients undergoing NACT were enrolled in a multimodal DOT and X-ray digital breast tomosynthesis (DBT) imaging study in which their breasts were imaged at different compression levels. Logistic regressions were used to study the associations between DOT-derived imaging markers evaluated after the first and second cycles of chemotherapy, respectively, with pCR status determined after the conclusion of NACT at the time of surgery. Receiver operating characteristic curve analysis was also used to explore the predictive performance of selected DOT-derived markers. Results: Normalized tumor HbT under half compression was significantly lower in the pCR group compared to the non-pCR group after two chemotherapy cycles ( Conclusions: These findings suggest that breast DOT could be used to assist response assessment in women undergoing NACT, a critical but unmet clinical need, and potentially enable personalized adjustments of treatment regimens.

Indexed as

Breast NeoplasmsNeoadjuvant TherapyTomography, OpticalAdultAgedBiomarkers, TumorBreastFemaleHemodynamicsHemoglobinsHumansMammographyMiddle AgedROC CurveTreatment OutcomeBiomarkers, TumorHemoglobinsbreast cancerdiffuse optical tomographydigital breast tomosynthesisfunctional imaging markerneoadjuvant chemotherapytherapy monitoring

Identifiers

PMID38737790
PMCPMC11088438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.